Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

7MM Autism Spectrum Disorder Market Opportunity Assessment and Forecast Report 2024-2034: Entry of the Five Pipeline Products Will Have a Significant Impact on the Market

globenewswire.com
ABR AbbVie's drug Abilify is mentioned as a current treatment option for ASD. The article does not provide specific sentiment towards AbbVie's performance or future prospects related to this drug. LLY PFG Procter & Gamble's drug fluoxetine (Prozac) is mentioned as a selective serotonin reuptake inhibitor (SSRI) used for ASD treatment. The article does not offer specific sentiment towards PFG or its future prospects. MRK Merck's drug atomoxetine is mentioned as a selective norepinephrine reuptake inhibitor (SNRI) for ASD treatment. The article does not provide specific sentiment towards Merck or its future prospects. JNJ CL Colgate-Palmolive's drug clonidine is mentioned as an alpha-2 agonist for ASD treatment. The article does not provide specific sentiment towards CL or its future prospects. AXSM Axsome Therapeutics' drug AXS-07 (deucravacitinib) is mentioned as a pipeline product for ASD. The article highlights the significant market opportunity and growth projected for new entrants, suggesting a positive outlook for companies with promising pipeline products. ACAD Acadia Pharmaceuticals' drug pimavanserin (Nuplazid) is mentioned as a pipeline product for ASD. The article highlights the significant market opportunity and growth projected for new entrants, suggesting a positive outlook for companies with promising pipeline products.

Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.

This report covers the 7MM and provides an Excel-based forecast model for the Autism Spectrum Disorder market through 2034.

The autism market is crowded with inexpensive generic products and off-label drugs. There are currently no approved therapies to target the core symptoms of ASD, warranting targeted drug development. In the late-stage pipeline (Phase IIb onwards), there are three products being developed to target the core symptoms of ASD. The ASD market across the 7MM was valued at $364.9 million in the 2024 baseline year.

Over the 10- year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 18.7%, reaching $2.0 billion by 2034. The entry of the five pipeline products during the forecast period will have a significant impact on the market. They are anticipated to contribute $1.7 billion in sales by 2034.

Report Scope

Reasons to Buy

Key Topics Covered:

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of ASD

3.2. Etiology and Pathophysiology of ASD

3.3. Diagnosis and Classification of ASD

3.4. ASD SWOT Analysis

4. Epidemiology

4.1. Diagnosed Prevalent Cases of ASD (N), Men and Women, All Ages, 2024-34

4.2. Age-Specific Diagnosed Prevalent Cases of ASD (N), Men and Women, 2024

4.3. Sex-Specific Diagnosed Prevalent Cases of ASD (N), All Ages, 2024

4.4. Sources Used to Forecast the Diagnosed Prevalent Cases of ASD

4.5. Sources and Methodology - Diagnosed Prevalent Cases of ASD

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Abilify (aripiprazole)

5.4. Product Profile: Risperdal (risperidone)

5.5. Product Profile: Other atypical antipsychotics

5.6. Product Profile: Selective serotonin reuptake inhibitors (fluoxetine, sertraline)

5.7. Product Profile: Selective norepinephrine reuptake inhibitors (atomoxetine)

5.8. Product Profile: Psychostimulants (methylphenidate hydrochloride)

5.9. Product Profile: Alpha-2 agonist (clonidine, guanfacine)

5.10. Patient Flow: ASD in 2024 Across the 7MM

6. Unmet Needs and Opportunities

6.1. Unmet Needs in ASD

6.2. Effective Treatment Options for the Core Symptoms of ASD

6.3. Treatment Options for Sleep Disturbances in ASD

6.4. Formulations Tailored for Pediatric ASD Patients

6.5. Improved Access to Behavioral Therapies

7. R&D Strategies

7.1. Trends in Clinical Trial Design in ASD

7.2. Trends in Deal-Making in ASD

8. Pipeline Assessment

8.1. ASD Pipeline Overview

8.2. Late-Stage Pipeline Agents for ASD

8.3. Product Profile: Vraylar/Reagila (cariprazine)

8.4. Product Profile: Caplyta (lumateperone)

8.5. Product Profile: Atypical antipsychotics (Vraylar/Reagila [cariprazine], Caplyta [lumateperone])

8.6. Product Profile: CM-AT/LUMINENZ-AT

8.7. Product Profile: PAX-101 (suramin hexasodium)

8.8. Product Profile: L1-79 (metyrosine)

8.9. Product Profile: ML-004 (zolmitriptan)

8.10. ASD Clinical Trials (Phase 0/I/II/III) Overview

9. Market Outlook

9.1. ASD Market Forecast

9.2. Market Drivers and Barriers

10. Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/deazzu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.